Insider · CIK 1738048
Venrock Healthcare Capital Partners III
- 10% owner at Lycia Therapeutics LYCA: 11 buys, 0 sales
- 10% owner at KalVista Pharmaceuticals KALV: 32 buys, 5 sales
- 10% owner at Oruka Therapeutics ORKA: 5 buys, 0 sales
- 10% owner at Altimmune ALT: 7 buys, 0 sales
- 10% owner at Cogent Biosciences COGT: 3 buys, 0 sales
- 10% owner at Company with CIK 1434418: 1 buys, 0 sales
Full history from EDGAR: holdings now, every transaction and Form 144 planned sales
Open-market buys59
Open-market sales5
Bought$96.8M
Sold$3.7M
Every trade, with what the company filed around it
Open-market buys and sales as each Form 4 states them, newest first.
How these figures work
Notes on each row are as each Form 4 states them, next to SEC Tracker's own records of the company's filings and other insiders' buys. Holding after is what the filing reports they held after the trade, with the change in their holding.
| Date | Company | Trade | Value | Holding after | Notes |
|---|---|---|---|---|---|
| Oct 30, 2026 | Lycia Therapeutics LYCA | Bought 9,004 sh at $26.28 The same day as the company's SCHEDULE 13G filed Oct 30, 2026. | $237K | The same day as the company's SCHEDULE 13G filed Oct 30, 2026. | |
| Oct 29, 2026 | Lycia Therapeutics LYCA | Bought 1,000 sh at $26.33 3 days after the company's 8-K filed Oct 26, 2026. | $26K | 6,841,233 +<1% | 3 days after the company's 8-K filed Oct 26, 2026. |
| Oct 28, 2026 | Lycia Therapeutics LYCA | Bought 15,000 sh at $25.45 2 days after the company's 8-K filed Oct 26, 2026. | $382K | 2 days after the company's 8-K filed Oct 26, 2026. | |
| Oct 27, 2026 | Lycia Therapeutics LYCA | Bought 39,796 sh at $26.62 1 day after the company's 8-K filed Oct 26, 2026. | $1.1M | 1 day after the company's 8-K filed Oct 26, 2026. | |
| Oct 26, 2026 | Lycia Therapeutics LYCA | Bought 1,952,705 sh at $18.04 The same day as the company's 8-K filed Oct 26, 2026. | $35.2M | The same day as the company's 8-K filed Oct 26, 2026. | |
| Oct 23, 2026 | Lycia Therapeutics LYCA | Bought 52,939 sh at $25.91 Their first open-market buy here in SEC Tracker's records. The same day as the company's 424B4 filed Oct 23, 2026. | $1.4M | Their first open-market buy here in SEC Tracker's records. The same day as the company's 424B4 filed Oct 23, 2026. | |
| Mar 26, 2026 | KalVista Pharmaceuticals KALV | Sold 21,386 sh at $17.76 The filing does not mark this sale as under a Rule 10b5-1 plan. 1 day after the company's 8-K filed Mar 25, 2026. | $380K | 5,107,954 −<1% | The filing does not mark this sale as under a Rule 10b5-1 plan. 1 day after the company's 8-K filed Mar 25, 2026. |
| Mar 26, 2026 | KalVista Pharmaceuticals KALV | Sold 15,417 sh at $18.82 The filing does not mark this sale as under a Rule 10b5-1 plan. 1 day after the company's 8-K filed Mar 25, 2026. | $290K | 5,092,537 −<1% | The filing does not mark this sale as under a Rule 10b5-1 plan. 1 day after the company's 8-K filed Mar 25, 2026. |
| Mar 26, 2026 | KalVista Pharmaceuticals KALV | Sold 3,183 sh at $19.12 The filing does not mark this sale as under a Rule 10b5-1 plan. 1 day after the company's 8-K filed Mar 25, 2026. | $61K | 5,089,354 −<1% | The filing does not mark this sale as under a Rule 10b5-1 plan. 1 day after the company's 8-K filed Mar 25, 2026. |
| Mar 25, 2026 | KalVista Pharmaceuticals KALV | Sold 174,485 sh at $16.95 The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as the company's 8-K filed Mar 25, 2026. | $3M | 5,129,500 −3% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as the company's 8-K filed Mar 25, 2026. |
| Mar 25, 2026 | KalVista Pharmaceuticals KALV | Sold 160 sh at $17.53 The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as the company's 8-K filed Mar 25, 2026. | $3K | 5,129,340 −<1% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as the company's 8-K filed Mar 25, 2026. |
| Apr 9, 2025 | KalVista Pharmaceuticals KALV | Bought 25,000 sh at $9.42 | $236K | 5,303,985 +<1% | |
| Feb 14, 2025 | Oruka Therapeutics ORKA | Bought 88,794 sh at $11.44 | $1M | 4,148,428 +2% | |
| Feb 13, 2025 | Oruka Therapeutics ORKA | Bought 14,950 sh at $11.63 | $174K | 4,059,634 +<1% | |
| Feb 13, 2025 | KalVista Pharmaceuticals KALV | Bought 61,700 sh at $9.33 | $576K | 5,278,985 +1% | |
| Feb 12, 2025 | Oruka Therapeutics ORKA | Bought 8,971 sh at $11.86 | $106K | 4,044,684 +<1% | |
| Feb 12, 2025 | KalVista Pharmaceuticals KALV | Bought 100,000 sh at $9.23 | $923K | 5,217,285 +2% | |
| Feb 11, 2025 | Oruka Therapeutics ORKA | Bought 9,593 sh at $10.95 | $105K | 4,035,713 +<1% | |
| Feb 11, 2025 | KalVista Pharmaceuticals KALV | Bought 26,703 sh at $9.18 | $245K | 5,117,285 +1% | |
| Feb 10, 2025 | Oruka Therapeutics ORKA | Bought 574 sh at $10.90 Their first open-market buy here in SEC Tracker's records. | $6K | 4,026,120 +<1% | Their first open-market buy here in SEC Tracker's records. |
| Feb 10, 2025 | KalVista Pharmaceuticals KALV | Bought 4,137 sh at $9.14 | $38K | 5,090,582 +<1% | |
| Feb 7, 2025 | KalVista Pharmaceuticals KALV | Bought 73,649 sh at $9.29 | $684K | 5,086,445 +1% | |
| Feb 3, 2025 | KalVista Pharmaceuticals KALV | Bought 14,562 sh at $9.22 | $134K | 5,012,796 +<1% | |
| Jan 31, 2025 | KalVista Pharmaceuticals KALV | Bought 11,754 sh at $8.89 | $104K | 4,998,234 +<1% | |
| Jan 30, 2025 | KalVista Pharmaceuticals KALV | Bought 43,707 sh at $8.76 | $383K | 4,986,480 +1% | |
| Feb 8, 2024 | KalVista Pharmaceuticals KALV | Bought 29,747 sh at $14.70 | $437K | 4,824,731 +1% | |
| Feb 7, 2024 | KalVista Pharmaceuticals KALV | Bought 51,827 sh at $14.56 | $755K | 4,794,984 +1% | |
| Feb 6, 2024 | KalVista Pharmaceuticals KALV | Bought 4,474 sh at $14.74 | $66K | 4,743,157 +<1% | |
| Jan 30, 2024 | KalVista Pharmaceuticals KALV | Bought 88,099 sh at $14.47 | $1.3M | 4,738,683 +2% | |
| Jan 29, 2024 | KalVista Pharmaceuticals KALV | Bought 80,600 sh at $14.22 | $1.1M | 4,650,584 +2% | |
| Jan 26, 2024 | KalVista Pharmaceuticals KALV | Bought 4,174 sh at $12.98 | $54K | 4,569,984 +<1% | |
| Jan 25, 2024 | KalVista Pharmaceuticals KALV | Bought 7,030 sh at $12.73 | $89K | 4,565,810 +<1% | |
| Jan 24, 2024 | KalVista Pharmaceuticals KALV | Bought 20,686 sh at $12.44 | $257K | 4,558,780 +<1% | |
| Jan 23, 2024 | KalVista Pharmaceuticals KALV | Bought 10,897 sh at $12.54 | $137K | 4,538,094 +<1% | |
| Jan 22, 2024 | KalVista Pharmaceuticals KALV | Bought 67,546 sh at $12.55 | $848K | 4,527,197 +2% | |
| Jan 19, 2024 | KalVista Pharmaceuticals KALV | Bought 25,000 sh at $12.43 | $311K | 4,459,651 +1% | |
| Jan 18, 2024 | KalVista Pharmaceuticals KALV | Bought 39,680 sh at $12.51 | $496K | 4,434,651 +1% | |
| Jan 17, 2024 | KalVista Pharmaceuticals KALV | Bought 78,925 sh at $12.60 | $994K | 4,394,971 +2% | |
| Jan 16, 2024 | KalVista Pharmaceuticals KALV | Bought 19,599 sh at $12.73 | $249K | 4,316,046 +<1% | |
| Jan 11, 2024 | KalVista Pharmaceuticals KALV | Bought 6,647 sh at $12.68 | $84K | 4,296,447 +<1% | |
| Jan 10, 2024 | KalVista Pharmaceuticals KALV | Bought 47,700 sh at $12.67 | $604K | 4,289,800 +1% | |
| Jan 9, 2024 | KalVista Pharmaceuticals KALV | Bought 20,816 sh at $12.56 | $261K | 4,242,100 +<1% | |
| Jan 8, 2024 | KalVista Pharmaceuticals KALV | Bought 69,184 sh at $12.44 | $861K | 4,221,284 +2% | |
| Jan 4, 2024 | KalVista Pharmaceuticals KALV | Bought 41,764 sh at $12.11 | $506K | 4,152,100 +1% | |
| Jan 3, 2024 | KalVista Pharmaceuticals KALV | Bought 17,605 sh at $12.20 | $215K | 4,110,336 +<1% | |
| Dec 29, 2023 | KalVista Pharmaceuticals KALV | Bought 6,013 sh at $12.49 | $75K | 4,092,731 +<1% | |
| Dec 28, 2023 | KalVista Pharmaceuticals KALV | Bought 471,490 sh at $12.50 | $5.9M | 4,086,718 +13% | |
| Dec 27, 2023 | KalVista Pharmaceuticals KALV | Bought 41,514 sh at $11.97 Their first open-market buy here in SEC Tracker's records. | $497K | 3,615,228 +1% | Their first open-market buy here in SEC Tracker's records. |
| Aug 18, 2020 | Cogent Biosciences COGT | Bought 101,000 sh at $2.62 | $265K | 4,355,273 +2% | |
| Aug 17, 2020 | Cogent Biosciences COGT | Bought 250,000 sh at $2.57 | $643K | 4,254,273 +6% | |
| Aug 14, 2020 | Cogent Biosciences COGT | Bought 100,000 sh at $2.30 Their first open-market buy here in SEC Tracker's records. | $230K | 4,004,273 +3% | Their first open-market buy here in SEC Tracker's records. |
| Jun 15, 2020 | Altimmune ALT | Bought 1,500,000 sh at $7.54 | $11.3M | 4,500,000 +50% | |
| May 28, 2020 | Altimmune ALT | Bought 201,474 sh at $8.72 | $1.8M | ||
| May 27, 2020 | Altimmune ALT | Bought 402,162 sh at $7.71 | $3.1M | ||
| May 26, 2020 | Altimmune ALT | Bought 700,000 sh at $9.34 Their first open-market buy here in SEC Tracker's records. | $6.5M | Their first open-market buy here in SEC Tracker's records. | |
| Dec 13, 2019 | Company with CIK 1434418 | Bought 400,000 sh at $34.50 Their first open-market buy here in SEC Tracker's records. | $13.8M | 4,016,873 +11% | Their first open-market buy here in SEC Tracker's records. |
Open-market trades are Form 4 transaction codes P (purchase) and S (sale). Planned sales are those the filing marks as made under a Rule 10b5-1 plan. A P-code buy at the offering price within a day of the company's FWP, 424B prospectus or offering 8-K is marked Bought in the offering and left out of open-market buy counts and cluster buys. Prices and values are as stated in each Form 4. Stock prices aren't shown on this page. Not investment advice.